Eli Lilly and Company (NYSE:LLY) is Trust Co. of Toledo NA OH’s 3rd Largest Position

Trust Co. of Toledo NA OH boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 28,725 shares of the company’s stock after purchasing an additional 33 shares during the quarter. Eli Lilly and Company comprises about 3.4% of Trust Co. of Toledo NA OH’s holdings, making the stock its 3rd biggest holding. Trust Co. of Toledo NA OH’s holdings in Eli Lilly and Company were worth $25,449,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Core Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $36,000. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $37,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth $40,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Trading Up 0.7 %

LLY stock opened at $891.01 on Thursday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The business has a 50 day simple moving average of $897.24 and a two-hundred day simple moving average of $846.22. The company has a market capitalization of $846.82 billion, a price-to-earnings ratio of 131.22, a PEG ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of the business’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 355,962 shares of company stock worth $331,267,535 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.